Market News & Trends
Harpoon Therapeutics Granted Orphan Drug Designation for Small Cell Lung Cancer Treatment
Harpoon Therapeutics, Inc. recently announced the US FDA has granted Orphan Drug Designation for HPN328, a delta like ligand 3- (DLL3) targeting TriTAC, for the…
Exclusive License for Croda to Commercialize SSI’s CAF® Vaccine Adjuvants
Croda International Plc, which uses smart science to improve lives, recently announces it has entered a strategic collaboration with Statens Serum Institut (SSI), the leading…
Fulcrum Therapeutics Announces Phase 3 Clinical Trial
Fulcrum Therapeutics, Inc. recently announced its plans to initiate REACH, a Phase 3 clinical trial of losmapimod in people with facioscapulohumeral muscular dystrophy (FSHD), in…
Aravive Announces Positive Updated Data & New Biomarker Data From Phase 1b Study
Aravive, Inc. recently announced positive new data from the Phase 1b portion of the ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell…
Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate
Skye Bioscience, Inc. has recently entered into an agreement with Novotech Health Holdings for its upcoming Phase 1 study in Australia of its SBI-100 drug…
Pii Announces New President & Chief Executive Officer
Pharmaceutics International Inc (Pii) recently announced its Board of Directors has appointed Mr. John Fowler as President and Chief Executive Officer effective March 7, 2022.…
Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma From Accure Therapeutics
Oculis S.A. and Accure Therapeutics recently announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease-modifying therapy to…
Harpoon Therapeutics Receives FDA Fast Track Designation
Harpoon Therapeutics, Inc. recently announced the US FDA has granted Fast Track designation to HPN217, a BCMA-targeting TriTAC, for the treatment of patients with relapsed,…
Enteris BioPharma to Participate in DCAT® Week 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq:…
Sterling Pharma Solutions Expands Global API Manufacturing Capabilities With Acquisition of Novartis Facility
Sterling Pharma Solutions recently announced it had reached agreement with Novartis to acquire its Ringaskiddy campus (Novartis Ringaskiddy Limited), near Cork, Ireland. Financial details of…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….